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TOS Motif-Mediated Raptor Binding Regulates 4E-BP1
Multisite Phosphorylation and Function
Drosophila or specific inhibition of mammalian TOR
(mTOR) by the immunosuppressant rapamycin results in
reduced cell size and cell proliferation [2–4]. The best-
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Cambridge, Massachusetts 02142 4E-BP1 functions as a repressor of translation; when
hypophosphorylated in the absence of nutrients or
growth factors, 4E-BP1 associates with eIF4E, the
mRNA cap binding protein, to inhibit cap-dependentSummary
translation [13, 14]. Binding of 4E-BPs to eIF4E is regu-
lated by ordered phosphorylation of critical proline-Background: The mammalian target of rapamycin,
directed Ser/Thr residues on 4E-BP1 [15, 16]. 4E-BP1mTOR, is a serine/threonine kinase that controls cell
contains at least six phosphorylation sites (Thr37, Thr46,growth and proliferation via the translation regulators
Ser65, Thr70, Ser83, and Ser112) [17, 18], four of whicheukaryotic initiation factor 4E (eIF4E) binding protein 1
(Thr37, Thr46, Ser65, and Thr70) are known to be regu-(4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). We
lated by mTOR signaling. Phosphorylation of Thr37 andrecently identified a TOR signaling (TOS) motif in the N
Thr46 is thought to prime 4E-BP1 for sequential phos-terminus of S6K1 and the C terminus of 4E-BP1 and
phorylation of Ser65 and Thr70, which results in thedemonstrated that in S6K1, the TOS motif is necessary
dissociation of 4E-BP1 from eIF4E [19, 20]. Free eIF4Eto facilitate mTOR signaling to phosphorylate and acti-
then forms an active translation initiation complex [21].vate S6K1. However, it is unclear how the TOS motif in
eIF4E function is particularly required for the efficientS6K1 and 4E-BP1 mediates mTOR signaling.
translation of transcripts containing highly structured 5Results: Here, we show that a functional TOS motif is
UTRs, a subset of which encode proteins involved in cellrequired for 4E-BP1 to bind to raptor (a recently identi-
growth and proliferation [22]. Indeed, overexpression offied mTOR-interacting protein), for 4E-BP1 to be effi-
eIF4E transforms rodent fibroblasts [23], while coex-ciently phosphorylated in vitro by the mTOR/raptor com-
pression with 4E-BP1 blocks eIF4E-driven transforma-plex, and for 4E-BP1 to be phosphorylated in vivo at all
tion [24].identified mTOR-regulated sites. mTOR/raptor-regu-
The mechanisms by which mTOR signals to its down-lated phosphorylation is necessary for 4E-BP’s efficient
stream targets, 4E-BP1 and S6K1, remain unclear. Di-release from the translational initiation factor eIF4E.
rect phosphorylation of 4E-BP1 and S6K1 by mTOR,Consistently, overexpression of a mutant of 4E-BP1
or indirect regulation of phosphorylation by an mTOR-containing a single amino acid change in the TOS motif
regulated kinase or phosphatase, has been suggested(F114A) reduces cell size, demonstrating that mTOR-
[19, 20]. Recently, new insights have emerged regardingdependent regulation of cell growth by 4E-BP1 is depen-
the biochemical mechanism by which mTOR signalingdent on a functional TOS motif.
is regulated. The regulatory associated protein of mTOR,Conclusions: Our data demonstrate that the TOS motif
raptor, and its yeast homolog, the Kontroller of Growth-1functions as a docking site for the mTOR/raptor com-
(KOG1), have been identified as novel TOR-interactingplex, which is required for multisite phosphorylation of
proteins and regulators [25–27]. Raptor association with4E-BP1, eIF4E release from 4E-BP1, and cell growth.
mTOR is required for efficient S6K1 and 4E-BP1 phos-
phorylation [25, 26] and has been suggested to function
Introduction as a scaffolding protein that brings mTOR in close prox-
imity to its substrates [26]. In addition, raptor was sug-
The coordination of cell growth (an increase in cell mass/ gested to function as a bidirectional regulator of mTOR,
size) and cell division (an increase in cell number) is inhibiting mTOR under nutrient starvation conditions
required for sustained cellular proliferation. The target of and activating it when adequate supplies of amino acids
rapamycin (TOR) is an evolutionarily conserved protein and carbohydrates are available [25]. Consistent with
serine/threonine kinase that integrates signals from nu- raptor’s ability to regulate TOR signaling and cell growth,
trients and mitogens to supply a required input for cell inhibition of raptor expression with siRNA reduces cell
growth and proliferation [1, 2]. Indeed, TOR deletion in size [25].
We recently identified a TOR signaling (TOS) motif in
the N terminus of all known S6 kinases and in the ex-*Correspondence: jblenis@hms.harvard.edu
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treme C terminus of the 4E-BPs [28]. The TOS motif of phorylation sites was also detected in U2OS cells (Fig-
ure 1C).S6K1 functions to receive mTOR signals, as mutagenic
inactivation of this motif mimics the effect of rapamycin To rule out the possibility that the inhibitory effect of
the TOS motif mutant (4E-BP1-F114A) on Ser65 andon S6K1 phosphorylation. S6K1 mutations that over-
come the inhibitory effect of the nonfunctional TOS motif Thr70 phosphorylation could be a secondary conse-
quence of reduced phosphorylation of the priming sitesrender S6K1 resistant to the inhibitory effect of amino
acid withdrawal and to rapamycin. We have also pre- (Thr37/46), we compared the phosphorylation of Ser65
and Thr70 in wild-type and 4E-BP1-F114A, which con-sented preliminary data that supports the finding that
mutation of Phe114 to Ala in the 4E-BP1 TOS motif tain acidic mutations in the priming sites Thr37/46 (4E-
BP1-T37/46E) to mimic Thr37/46 phosphorylation. It has(FEMDI) significantly inhibits insulin-stimulated phos-
phorylation of 4E-BP1 [28]. been reported that mutation of Thr37/46 to glutamic
residues (4E-BP1-T37/46E) partially restores phosphor-Here, we analyze in greater detail the mechanism by
which the TOS motif mediates 4E-BP1 phosphorylation ylation of Ser65 and Thr70, whereas mutation of Thr37/
46 to alanines abolishes phosphorylation of Ser65 andand function. We show that the TOS motif is required
for phosphorylation of 4E-BP1 in vitro and in vivo at Thr70 [15]. Phosphorylation of Ser65 and Thr70 in the
TOS motif mutant containing acidic Thr37/46 mutationsall the identified mTOR-regulated sites. The inability of
mTOR to regulate 4E-BP1 phosphorylation in a TOS (4E-BP1-F114A) was significantly less than in a 4E-BP1
mutant with the acidic substitutions for Thr37/46 butmotif mutant (F114A) correlates with the inability of rap-
tor to interact with 4E-BP1. Importantly, overexpression with a functional TOS motif; this finding suggests that
the TOS motif is required for efficient phosphorylationof 4E-BP1 (F114A) reduces cell size, similar to that ob-
served when the dominant-inhibitory 4E-BP1 mutant of Ser65 and Thr70 even when 4E-BP1 is primed by
phosphorylation at Thr37/46. Therefore, the TOS motif(T37/46A) was overexpressed [2]. These results eluci-
date the mechanism by which mTOR controls the phos- is required for mTOR-dependent phosphorylation of 4E-
BP1 at all known rapamycin-sensitive sites (Figures 1B–phorylation state of 4E-BP1 within mammalian cells: the
TOS motif mediates 4E-BP1/raptor association to drive 1D); this new role of the TOS motif is similar to its role
in regulating the phosphorylation status of several sitesmTOR-dependent multisite phosphorylation of 4E-BP1,
resulting in eIF4E release and cell growth. in S6K1 [28].
A Functional TOS Motif Is RequiredResults
for 4E-BP1/Raptor Complex Formation
How does the TOS motif mediate mTOR regulation ofTOS Motif Is Required for 4E-BP1 Phosphorylation
at All mTOR-Regulated Sites 4E-BP1? Recently, raptor and its yeast homolog KOG1
were identified as TOR-interacting proteins and regula-mTOR regulates hierarchical 4E-BP1 phosphorylation
(Thr37/46, Ser65, and Thr70), which is required for 4E- tors [25, 26]. Raptor forms a complex with 4E-BP1 and
mTOR [26] and is thought to function as a scaffoldingBP1’s release from eIF4E [19]. To investigate which
phosphorylation events on 4E-BP1 require the TOS motif protein that recruits mTOR in close proximity to its
downstream substrates [26]. To investigate whether the(Figure 1A), we analyzed the phosphorylation of the non-
functional TOS motif-containing mutant, 4E-BP1-F114A, TOS motif is required for 4E-BP1 regulation by the
mTOR/raptor complex, we cotransfected HA-taggedby employing various 4E-BP1 phospho-specific anti-
bodies. Basal and insulin-stimulated Thr37/46 phos- 4E-BP1 and myc-tagged raptor in HEK293E cells. The
TOS motif mutant 4E-BP1 (F114A) failed to coimmuno-phorylation was reduced in the 4E-BP1-F114A mutant pro-
tein when compared to wild-type 4E-BP1 in HEK293E cells precipitate with raptor, whereas wild-type 4E-BP1 coim-
munoprecipitated, as previously reported (Figures 2A,(Figure 1B). The F114A mutation had a more pronounced
inhibitory effect on phosphorylation of the later 4E-BP1 2B, and 2D; [26]), indicating that the TOS motif in 4E-
BP1 is required for its binding to raptor. The inability ofphosphorylation sites Thr70 and Ser65 (Figure 1B), of
which residual phosphorylation was only detected on 4E-BP1-F114A to bind to raptor is not a consequence
of its hypophosphorylated status, as the similarly hypo-longer film exposures (data not shown). Therefore, the
TOS motif is required for efficient 4E-BP1 phosphoryla- phosphorylated 4E-BP1-T37/46A mutant bound raptor
as efficiently as wild-type 4E-BP1 (Figure 2A). We havetion at all mTOR-regulated sites. The residual phosphor-
ylation of Thr37/46 (Figures 1B and 1C), Ser65, and Thr70 also generated mutations in other residues within the
TOS motif of 4E-BP1 and have tested their effect on 4E-(data not shown) in 4E-BP1-F114A was still sensitive to
the mTOR inhibitor, rapamycin, suggesting that either BP1 phosphorylation (as assayed by enhanced mobility
on SDS-PAGE) and 4E-BP1 coimmunoprecipitation withthe single F114A point mutation of the TOS motif does
not completely block the function of this TOS motif to myc-tagged raptor. Paralleling their effect on 4E-BP1
phosphorylation, different mutations in the TOS motifmediate mTOR-dependent phosphorylation of 4E-BP1 or
that the rapamycin-sensitive phosphorylation of Thr37/46, inhibited the ability of 4E-BP1 to coimmunoprecipitate
with raptor (Figures 2B and 2C). Importantly, the TOSSer65, and Thr70 can also occur independently of this
motif. TOS motif-independent dephosphorylation of 4E- motif was also required for 4E-BP1 to bind raptor under
conditions [25] that preserve mTOR complexes (0.2%BP1 could be caused by a rapamycin-activated, and
thus mTOR-inhibited, phosphatase. Regulation of 4E-BP1 CHAPS as detergent and crosslinker DSP). Upon cotrans-
fection of 4E-BP1-F114A and -WT with raptor, followedphosphorylation by such a phosphatase has already
been suggested [29, 30]. Similar regulation of these phos- by lysis under these conditions, raptor and endogenous
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Figure 1. TOS Motif Is Required for Multisite
4E-BP1 Phosphorylation
(A) A schematic model of 4E-BP1 and the
TOS motif, mTOR-regulated phosphorylation
sites (Thr37/46, Ser65, and Thr70), and the
eIF4E binding site (eIF4E-bindg.).
(B and C) (B) HEK293E or (C) U2OS cells were
transfected with wild-type HA-4E-BP1 (WT)
and HA-4E-BP1-F114A (F114A). Transfected
cells were starved, rapamycin treated, stimu-
lated, and lysed as described in the Experi-
mental Procedures. Protein expression levels
were assayed by immunoblotting with anti-
HA antibody (upper panels). In vivo phos-
phorylation of 4E-BP1 at Thr37/46 (anti-
P-Thr37/36), Ser65 (anti-P-Ser65), and Thr70
(anti-P-Thr70) was evaluated by immunoblot-
ting with 4E-BP1 phosphopeptide-specific
antibodies.
(D) HEK293E cells were transfected with HA-
4E-BP1-T37/46E (T37/46E) and HA-4E-BP1-
F114A-T37/46E (F114A-T37/46E). Transfected
cells were starved, rapamycin treated, stimu-
lated, and lysed as described in the Experi-
mental Procedures. Protein expression levels
were assayed by immunoblotting with anti-
HA antibody (upper panel). In vivo Ser65 (anti-
P-Ser65) and Thr70 (anti-P-Thr70) phosphor-
ylation was evaluated by immunoblotting with
phosphopeptide-specific antibodies.
mTOR coimmunoprecipitated with wild-type, but not GST-4E-BP1 (Figure 3A; [26]). Interestingly, AU-mTOR/
myc-raptor immunocomplexes did not enhance thewith the TOS motif mutant of 4E-BP1 (Figure 2D). Our
data indicate that a functional TOS motif is required for phosphorylation of GST-4E-BP1-F114A as potently as
wild-type GST-4E-BP1 under the same conditions in4E-BP1/raptor complex formation.
vitro (approximately 8 times lower). Importantly, the ki-
nase-inactive mutant of mTOR (AU-mTOR-KD) did notTOS Motif Is Required for Efficient In Vitro
phosphorylate GST-4E-BP1 or GST-4E-BP1-F114A (Fig-Phosphorylation of 4E-BP1 by mTOR
ure 3A), indicating that mTOR, rather than an associatedSince the TOS motif is required for efficient 4E-BP1
kinase, directly phosphorylates GST-4E-BP1 in thisphosphorylation at all mTOR-regulated sites in vivo (Fig-
assay. In contrast, activated recombinant ERK2 phos-ures 1B, 1C, and 1D), we next examined whether the
phorylated both wild-type 4E-BP1 [17] and the TOS motifTOS motif is required for mTOR phosphorylation of 4E-
mutant F114A to a similar extent (Figure 3B), indicatingBP1 in vitro. We compared the phosphorylation of re-
that the proline-directed sites in both recombinant pro-combinant wild-type GST-4E-BP1and GST-4E-BP1-
teins are accessible for phosphorylation. As expected,F114A by AU-tagged mTOR immunoprecipitated from
we did not detect phosphorylation of GST alone bycells transfected with AU-mTOR in the absence or pres-
mTOR or ERK2 (Figures 3A and 3B). Immunoprecipitatedence of myc-raptor. Importantly, we prepared cell ex-
endogenous mTOR from HEK293E cells also phosphor-tracts under conditions that retain the mTOR/raptor
ylated wild-type GST-4E-BP1 much more efficiently thancomplex, and, indeed, myc-raptor coimmunprecipita-
the F114A mutant (data not shown).tetd with AU-mTOR (Figure 3A; [25]) (We have noted that
the myc-antibody cross-reacts with a weak nonspecific
band that runs at about the size of raptor). AU-mTOR Mutation of the TOS Motif Strengthens the Binding
of 4E-BP1phosphorylated wild-type GST-4E-BP1 to a much
greater extent than GST-4E-BP1-F114A (Figure 3A); this Next, we investigated whether the 4E-BP1-F114A mu-
tant could inhibit eIF4E function under conditions infinding indicates that direct phosphorylation of 4E-BP1
by mTOR requires an intact TOS motif. As previously which wild-type 4E-BP1 does not, as during insulin stim-
ulation. We compared the association of wild-type 4E-reported, AU-mTOR/myc-raptor immunocomplexes sig-
nificantly enhance in vitro phosphorylation of wild-type BP1 and 4E-BP1-F114A to eIF4E by a m7GTP-Sepharose
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Figure 2. A Functional TOS Motif Is Required for 4E-BP1 to Bind to Raptor
(A) HEK293E cells were cotransfected with myc-raptor and either wild-type HA-4E-BP1 (WT), HA-4E-BP1-F114A (F114A), HA-4E-BP1-T37/
46A (T37/46A), or the empty pACTAG-2 vector (vector). Transfected cells were starved and stimulated as described in the Experimental
Procedures and lysed in buffer A as described in the Supplemental Data. Anti-HA immunoprecipitations were analyzed by anti-HA (4EBP1)
and anti-myc (myc-raptor) immunoblotting. Myc-raptor and HA-4E-BP1 expression levels was assayed by immunoblotting of cell lysate with
anti-myc antibody and anti-HA antibody, respectively.
(B) HEK293E cells were cotransfected with myc-raptor and either wild-type HA-4E-BP1 (WT), HA-4E-BP1-F114A (F114A), HA-4E-BP1-I118A
(I118A), or HA-4E-BP1-M116A/I118A (M116A/I118A). Transfected cells were starved and stimulated as described in the Experimental Procedures
and lysed in buffer A as described in the Supplemental Data. -myc immunoprecipitations were analyzed by anti-HA (4E-BP1) and anti-
myc (myc-raptor) immunoblotting. Protein expression levels were assayed by immunoblotting cell lysate with anti-myc antibody. Ser65
phosphorylation was evaluated by immunoblotting with anti-4E-BP1-P-Ser65 phosphopeptide-specific antibody.
(C) HEK293E cells were transfected with wild-type HA-4E-BP1 (WT), HA-4E-BP1-F114A (F114A), HA-4E-BP1-I118A (I118A), and HA-4E-BP1-
M116A/I118A (M116A/I118A). Transfected cells were starved, rapamycin treated, stimulated as described in the Experimental Procedures and
lysed in buffer A as described in the Supplemental Data. 4E-BP1 was detected by immunoblotting with anti-HA antibody.
(D) HEK293E cells were cotransfected with myc-raptor and either wild-type HA-4E-BP1 (WT), HA-4E-BP1-F114A (F114A), or the empty pACTAG-2
vector (vector). Transfected cells were starved and stimulated as described in the Experimental Procedures and lysed in buffer B containing
0.2% CHAPS as detergent and the chemical crosslinker DSP as described in the Supplemental Data. Anti-HA immunoprecipitations were
analyzed by anti-myc (myc-raptor) and anti-mTOR immunoblotting. Myc-raptor expression levels were assayed by immunoblotting of cell
lysate with anti-myc antibody.
pull-down assay. m7GTP mimics the cap structure of tion of wild-type 4E-BP1 to eIF4E in serum-starved cells
(Figure 4). As a negative control, we mutated the eIF4EmRNA and can be used to affinity purify eIF4E and its
associated proteins. In serum-starved HEK293E cells, binding site (4E-BP1-Y54A/L59A) on 4E-BP1 [31]. Bind-
ing of both wild-type and 4E-BP1-F114A to eIF4E waswild-type 4E-BP1 associated with eIF4E, which was ab-
rogated upon insulin stimulation but was recovered abrogated by Y54A/L59A mutations (Figure 4). These
data suggest that 4E-BP1-F114A binds to eIF4E specifi-when cells were pretreated with rapamycin, as expected
(Figure 4). The 4E-BP1-F114A mutant displayed stronger cally via the defined eIF4E binding site and therefore
functions as an inhibitor of eIF4E. Similar data wereassociation to eIF4E than wild-type 4E-BP1 in serum-
starved or rapamycin-treated HEK293E cells; this find- observed by using U2OS cells (data not shown).
ing is consistent with decreased phosphorylation on
the 4E-BP1-F114A mutant (Figures 1B, 1C, and 4). The Overexpression of 4E-BP1-F114A
Reduces Cell Sizeamount of 4E-BP1-F114A bound to eIF4E decreased
upon insulin stimulation of serum-starved HEK293E Reduction of raptor expression by siRNA [25] or inhibi-
tion of mTOR-dependent signaling with rapamycin [2]cells, but significant binding was still detectable. Indeed,
the association of 4E-BP1-F114A to eIF4E in insulin- results in reduced cell size, suggesting that raptor medi-
ates mTOR-dependent regulation of cell growth. To de-stimulated cells was significantly higher than associa-
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Figure 3. TOS Motif Is Required for 4E-BP1 In Vitro Phosphorylation by mTOR, but not ERK2
(A) AU-mTOR wild-type (WT) or kinase-dead (KD) coexpressed in HEK293E cells with myc-raptor or vector control were purified by anti-AU
immunoprecipitation and were subjected to an in vitro mTOR kinase assay with recombinant wild-type GST-4E-BP1, GST-4E-BP1-F114A, or
GST as substrates as described in the Supplemental Data. Quantification of the kinase assay (first panel) and autoradiogram of phosphorylated
proteins (second panel) is shown. Coomassie staining of the SDS-PAGE gel reveals the relative amounts of each fusion protein in the assay
(third panel). An anti-AU immunoblot of the kinase assay (fourth panel) is shown.
(B) In vitro phosphorylation of recombinant wild-type GST-4E-BP1, GST-4E-BP1-F114A, and GST by activated (His)6-ERK2 was performed as
described in the Supplemental Data. Quantification of the kinase assay (first panel) and an autoradiogram of phosphorylated proteins (second
panel) are shown. Coomassie staining of the SDS-PAGE gel reveals the relative amounts of each fusion protein in the assay (third panel).
termine whether TOS-mediated 4E-BP1 phosphoryla-
tion by the mTOR/raptor complex is important for the
control of cell growth, we tested whether overexpres-
sion of 4E-BP1-F114A would reduce the size of prolifer-
ating U2OS cells. We used U2OS cells for this study as
their cell size is fairly homogenous and they have been
well characterized for cell size regulation by mTOR sig-
naling [2]. Furthermore, we have shown that the regula-
tion of 4E-BP1 phosphorylation is similar in U2OS and
HEK293 cells (Figures 1B and 1C). The relative size of
G1 phase cells was measured by flow cytometry with
the parameter forward scatter-height. We first com-
pared the FSC-H histogram of cells transfected with
pACTAG-2 vector control to those treated with rapa-Figure 4. Mutation of the TOS Motif Induces Stronger Binding to
eIF4E mycin or transfected with 4E-BP1-T37/46, -WT, or -F114A
HEK293E cells overexpressing wild-type HA-tagged 4E-BP1 (WT) (Figure 5A). Overexpression of 4E-BP1-F114A induced
and HA-tagged 4E-BP1 mutants (F114A, Y54A/L59A, or F114A- a shift to reduced cell size compared to vector control
Y54A/L59A) were starved, rapamycin treated, stimulated, and lysed (Figure 5A), and this is similar to the previously reported
as described in the Experimental Procedures. Protein expression effect that rapamycin or the dominant 4E-BP1-T37/46A
levels were assayed by immunoblotting with anti-HA antibody (top
mutant has on reducing cell size [2]. 4E-BP1-WT hadpanel). m7GTP-Sepharose pull down was analyzed by immunoblot-
a minimal effect, which was also previously reported.ting for anti-HA (HA-4E-BP1) (middle panel) and anti-eIF4E (bottom
panel). Graphical representation of the same experiment whereby
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Figure 5. Overexpression of 4E-BP1-F114A Causes Reduction of Cell Size
(A–C) U2OS cells were cotransfected with 1 g CD20 and 10 g of either the empty pACTAG-2 vector (vector), wild-type HA-4E-BP1 (WT),
HA-4E-BP1-F114A (F114A), or HA-4E-BP1-T37/46A (T37/46A) (A and B) or with 1 g CD20 and either 10 g of the empty pACATG-2 vector
(vector), wild-type HA-4E-BP1 (WT), or the following HA-4E-BP1 mutants: F114A, F114A-Y54A/L59A, or Y54A/L59A (C). After overnight
transfection, cells were split to new plates containing DMEM/FBS to allow subconfluent proliferation for 72 hr and were assayed by flow
cytometry to determine cell size. In (A) and (B), vector-transfected cells were cultured in the absence or presence of rapamycin (rap); in (B) and
(C), the mean FSC-H  SD of triplicate transections is shown. Panel (A) depicts FSC-H histograms of representative samples shown in (B).
each construct was transfected in triplicate shows tion by the mTOR/raptor complex. Additionally, we dem-
onstrate that mTOR signaling via the TOS motif is impor-that the reduction in cell size induced by 4E-BP1-F114A
expression is significant (Figure 5B). Importantly, muta- tant for the complete insulin-stimulated release of 4E-
BP1 from eIF4E, which is a prerequisite for proper celltions of the eIF4E binding domain (Y54A/L59A) on 4E-BP1
abrogated the ability of the TOS motif mutant 4E-BP1- growth control (Figures 4 and 5A–5C). Consistently, ex-
pression of 4E-BP1 containing a mutated TOS motifF114A to reduce cell size (Figure 5C), demonstrating that
the growth inhibitory effect caused by 4E-BP1-F114A reduces cell size (Figures 5A–5C).
Which phosphorylation sites on 4E-BP1 are regulatedoccurs specifically through eIF4E binding and thus inhi-
bition of eIF4E function. These data indicate that the by mTOR signaling remains controversial. Recent data
demonstrate that raptor is important for the regulationTOS motif is important for regulation of 4E-BP1’s biolog-
ical function, to control cell growth. of mTOR’s function [25, 32]. Hara et al. [26] suggest
that raptor functions as a scaffolding protein, recruiting
mTOR to its substrates S6K1 and 4E-BP1. Kim et al.Discussion
[25] suggest an additional function for raptor as a bidi-
rectional modulator of mTOR: raptor association is re-The role of the recently identified TOS motif within 4E-
BP1 to regulate its phosphorylation and function has not quired for mTOR function under nutrient-rich conditions
but represses mTOR kinase activity through a secondbeen defined. We find that the TOS motif is absolutely
required for efficient phosphorylation of 4E-BP1 at all high-affinity interaction under nutrient-poor conditions.
Based on the data presented here and on previous ob-the identified mTOR-regulated sites, namely, Thr37/46,
Ser65, and Thr70 in vivo (Figures 1B, 1C, and 1D). Only servations [25, 26, 33], we propose the following model
(Figure 6): the TOS motif mediates 4E-BP1 binding to4E-BP1 with an intact TOS motif coimmunoprecipitates
with raptor (Figures 2A, 2B, and 2D) and is efficiently raptor, which in turn recruits mTOR to the 4E-BP1/raptor
complex. At this time, we do not know whether 4E-BP1phosphorylated by mTOR in vitro (Figure 3A), indicating
that the TOS motif is required for 4E-BP1 phosphoryla- directly binds to raptor or whether the binding is indirect
The 4E-BP1 TOS Motif Mediates Raptor Binding
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Figure 6. Model of 4E-BP1 Regulation by
mTOR Signaling
The mTOR/4E-BP1/raptor complex exists in
two forms under amino acid-rich conditions.
In serum-starved cells, mTOR directly phos-
phorylates the 4E-BP1 priming sites Thr37/
46. Insulin/serum stimulation leads to phos-
phorylation of Ser65 and Thr70 by an mTOR-
regulated kinase (kinase X) and/or by inhibi-
tion of an mTOR-regulated phosphatase
(PPtase). Phosphorylation of Thr37/46, Ser65,
and Thr70 induces dissociation of eIF4E from
4E-BP1. At this point, it is not known whether
the association of 4E-BP1 with raptor is direct
or indirect.
and thus mediated by another molecule or molecules Thr70 has been suggested to be regulated by an mTOR-
regulated kinase [35] (kinase X in model in Figure 6) and/in the complex. This recruitment of mTOR enables direct
and/or indirect phosphorylation of 4E-BP1 at Thr37/46, or by a mTOR-regulated phosphatase [29] (PPtase in
model in Figure 6).Ser65, and Thr70. In support of this model, the TOS
motif 4E-BP1 mutant (4E-BP1-F114A) fails to coimmu- The RAIP motif in the N terminus of 4E-BP1 and 4E-
BP2 has been found to be critical for 4E-BP1 phosphory-noprecipitate with raptor, resulting in reduced in vitro
phosphorylation of 4E-BP1 by mTOR (Figures 2A, 2B, lation on mTOR-regulated sites [37]. In contrast to the
TOS motif mutant, which has a more pronounced inhibi-2D, and 3A) and reduced phosphorylation of 4E-BP1 at
Thr37/46, Ser65, and Thr70 in vivo (Figures 1B and 1C). tory effect on the phosphorylation of Ser65 and Thr70,
deletion or mutation of the RAIP motif significantly inhib-The high basal phosphorylation of Thr37/46 in serum-
starved cells is significantly reduced in the 4E-BP1- its mitogen-stimulated phosphorylation of the priming
sites Thr37/46. Therefore, it is likely that the RAIP motifF114A mutant (Figure 1B); this finding suggests that the
TOS motif is absolutely required for Thr37/46 phosphor- mediates phosphorylation of Thr37/46 by a mitogen-
stimulated kinase.ylation under serum-starved conditions. Under amino
acid-rich but serum-starved conditions, mTOR likely The TOS motif on S6K1 was also found to be important
for phosphorylation of several structurally diverse sites,forms a constitutively active complex with raptor that
directly phosphorylates 4E-BP1 at the Thr37/46 priming and this importance is consistent with the possibility that
mTOR also dynamically regulates S6K1 via activation ofsites to allow for additional mitogen-stimulated phos-
phorylation (see model: Figure 6; [26]). Consistently, a kinase and via inhibition of a phosphatase [28]. It
has been reported that S6K1 activation requires raptormTOR immunoprecipitates have been shown to phos-
phorylate 4E-BP1 at Thr37/46 in vitro [10, 34, 35]. The association [25, 26], making it likely that the TOS motif
within S6K1 is required for S6K1/raptor complex forma-residual insulin-stimulated phosphorylation on 4E-BP1-
F114A could be mediated by an insulin/mitogen-stimu- tion. Consistent with the results reported by Hara et al.
[26], we also detect weak binding of wild-type S6K1 tolated kinase that phosphorylates Thr37/46 independently
of the TOS motif (Figures 1B and 1C). The existence raptor (data not shown). Unfortunately, this weak inter-
action makes it experimentally difficult for us to charac-of a serum-stimulated, mTOR-independent kinase for
Thr37/46 has also been previously suggested [19, 36]. terize the contribution of the S6K1 TOS motif to raptor
binding. This difference in raptor binding affinity to S6K1In contrast, phosphorylation of Ser65 and Thr70 ap-
pears to be more dependent on mTOR signaling, since and 4E-BP1 could be caused by the different composi-
tions of mTOR/S6K1/raptor or mTOR/4E-BP1/raptorphosphorylation of these sites in the TOS motif mutant
(4E-BP1-F114A) is more strongly reduced under serum- complexes, with additional molecules found specifically
in one or the other complex, or as a result of the exis-starved and insulin-stimulated conditions (Figures 1B
and 1C). Mimicking Thr37/46 phosphorylation with tence of additional binding determinants in 4E-BP1.
4E-BP1 functions to regulate cell growth/cell size andacidic amino acid substitutions does not rescue Ser65
and Thr70 phosphorylation in the 4E-BP1-F114A mutant cellular proliferation [2, 38]. Overexpression of 4E-BP1
antagonizes transformation induced by eIF4E overex-(Figure 1D); this finding demonstrates that the TOS mo-
tif’s effect on Ser65 and Thr70 is not merely a secondary pression [24], and overexpression of dominant-negative
4E-BP1 mutants in cycling mammalian U2OS cells [2] orconsequence of its effect on Thr37/46 phosphorylation.
Ser65 and Thr70 are not likely directly phosphorylated Drosophila [38] reduces cell size. Here, we demonstrate
that 4E-BP1 regulation by mTOR via the TOS motif isby mTOR, given that mTOR is not active on these sites
in vitro (Figure 6; [34]). Phosphorylation of Ser65 and required for 4E-BP1-mediated control of cell size. Over-
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Cell Culture and Transfectionexpression of 4E-BP1-F114A reduced the size of G1
HEK293E were cultured, transfected, and lysed for immunoblottingphase-gated U2OS cells in a manner similar to the domi-
and coimmunoprecipitation as described previously [43], and hu-nant-negative 4E-BP1 mutant 4E-BP1-T37/46A (Figures
man U2OS osteosarcoma cells were cultured, transfected, and lysed
5A and 5B). The effect of 4E-BP1-F114A overexpression as described in [2]. Human U2OS osteosarcoma cells were seeded
on cell growth is consistent with the lack of 4E-BP1 on 60-mm dishes 1 day prior to transfection with Fugene (Roche)
overnight according to the manufacturer’s directions by using 3–10phosphorylation by mTOR via the TOS motif, as several
g total DNA, depending on the experiment. After 20 hr of starvationof these phosphorylation events are required to release
in serum-free DMEM, cells were pretreated for 30 min with rapa-eIF4E and promote cap-dependent translation [16, 39].
mycin (provided by S.N. Seghal, Wyeth-Ayerst) (20 ng/ml) or ethanolMutation in the eIF4E binding site on 4E-BP1-F114A
vehicle, then stimulated with 100 nM insulin (HEK293E) or 10% FBS
(4E-BP1-F114A-Y54A/L59A), although still hypophos- (U2OS) for 30 min.
phorylated, abrogated its ability to bind to eIF4E and to
reduce cell size (Figure 5C). Thus, the growth inhibitory Immunoblots
effect of 4E-BP1-F114A is mediated via its constitutive Proteins were resolved by SDS-12% polyacrylamide gel electropho-
resis (PAGE), transferred to nitro-cellulose (Schleicher and Schuell),binding to and inhibition of eIF4E.
probed with the indicated antibodies, and then detected with HRP-
conjugated secondary antibody.
Conclusions
CoimmunoprecipitationsIn this study, we identify a docking site on 4E-BP1 that
The coimmunoprecipitation assays were carried out as describedis required for raptor association and thus clarify the
in the Supplemental Data available with this article online.
mechanism by which the mTOR substrate 4E-BP1 is
regulated by the mTOR/raptor complex. TOS motif-
Immune Complex Kinase Assay
mediated 4E-BP1 complex formation with raptor re- The immune complex kinase assay was carried out as described in
cruits 4E-BP1 to the mTOR kinase. The association of the Supplemental Data available with this article online.
4E-BP1 with the mTOR/raptor complex is required for
efficient phosphorylation of 4E-BP1 at several diverse m7GTP Cap Binding Assays
sites, probably via different mTOR-dependent mecha- Cell extracts were incubated with 30 l m7GTP-Sepharose CL4B
beads (Amersham Pharmacia Biotech) at 4C for 1 hr, then washednisms. Importantly, we demonstrate that regulation of
twice in 1 ml buffer E (10 mM Tris, 100 mM NaCl, 1% NP-40, 1 mM4E-BP1 phosphorylation by the TOS motif is biologically
EDTA, 0.5% sodium deoxycholate, 2 mM DTT, 1 mM sodium ortho-significant: expression of 4E-BP1-F114A reduces cell
vanadate, 40 mg/ml PMSF, 10 g/ml leupeptin, 5 g/ml pepstatin
size, indicating that the TOS motif is crucial for regula- [pH 7.2]) and once in 1 ml ST. Sepharose beads were resuspended
tion of cell growth by mTOR/raptor signaling. The TOS in Laemmli sample buffer with 2% -ME and were resolved on SDS-
motif appears to function as a general motif that allows PAGE.
raptor to bring downstream substrates to mTOR. In the
Flow Cytometryfuture, we hope to identify novel mTOR substrates by
Relative cell size was determined by using the parameter meanusing our mechanistic knowledge of the TOS motif.
forward scatter-height (FSC-H) using a Becton Dickinson FACS Cali-
bur flow cytometer with Cell Quest software, as previously described
[2]. Briefly, 4  105 U2OS cells were plated to 60-mm plates 1 dayExperimental Procedures
prior to transfection with Fugene reagent (Roche) by using 10 g
pACTAG2 plasmids and 1 g CD20. After overnight transfection,Plasmids and Fusion Proteins
60-mm plates were split 1:4 to 10-cm plates to allow subconfluentpcDNA3/AU-mTOR encoding wild-type (WT) and kinase-dead (KD,
proliferation for 72 hr. After 72 hr, cells were harvested for FACSD2338A) mTOR were kindly provided by Robert Abraham (Burnham
analysis by staining with anti-CD20-FITC antibodies, followed byInstitute, San Diego, CA) and have been described [10]. pACTAG-2/
fixation in ethanol. Immediately prior to FACS analysis, samples3HA-4E-BP1-WT (4E-BP1), pACTAG-2/3HA-4E-BP1-T37/46E (4E-
were treated with propidium iodide and RNaseA.BP1-EE), and pACTAG-2/3HA-4E-BP1-T37/46A (4E-BP1-T37/46A)
were generously provided by Nahum Sonenberg (McGill University,
Montreal, Quebec, Canada) and are described in [15]. Andy R. Tee Supplemental Data
(Harvard Medical School, Boston) generated GST-4E-BP1 by sub- Supplemental Data including a detailed description of the coimmu-
cloning human 4E-BP1 into pGEX-2T/GST. Point mutations of 4E- noprecipitation procedure and the immune complex kinase assay
BP1 were generated by site-directed mutagenesis as described in are available at http://images.cellpress.com/supmat/supmatin.htm.
the manufacture’s protocol (Stratagene). pRK5/myc-raptor (human)
has been described [25]. Recombinant wild-type GST-4E-BP1 and
AcknowledgmentsGST-4E-BP1-F114A were purified from E. coli. pET(His)6/ERK2 was
provided by M.H. Cobb [40] and was purified as described in [41].
We thank Robert Abraham for his generous donation of mTOR plas-
mids, Nahum Sonenberg for generously sharing the 4E-BP1 plas-
mids, and Leon Murphy, Celeste Richardson, and Andy Tee forAntibodies
helpful discussions and a critical reading of the manuscript. We alsoAnti-myc monoclonal antibodies were purchased from Charles River
thank Leon Murphy for the recombinant (His)6-ERK2. This work wasLaboratories. Anti-HA monoclonal antibodies were kindly provided
supported by National Institutes of Health (NIH) grant GM51405 (toby Margaret Chou (University of Pennsylvania, Philadelphia). The
J.B.), National Research Service Award Postdoctaral Fellowship,anti-4E-BP1-phospho-Thr37/46, -phospho-Ser65, -phospho-Thr70,
NIH #F32 CA-69808 (to D.C.F.), and the Boehringer Ingelheim Fonds,and anti-eIF4E antibodies were obtained from Cell Signaling Tech-
Germany (to S.S.S.).nology. The anti-AU1 antibody was purchased from Covance, and
the anti-MAPK antibodies have been described [42]. Anti-mTOR
antibodies were purchased from Santa Cruz Biotechnology. For Received: January 20, 2003
Revised: March 3, 2003immunoblotting, anti-rabbit and anti-mouse horseradish peroxidase
(HRP)-conjugated secondary antibodies were purchased from Accepted: March 20, 2003
Published: May 13, 2003Amersham and Chemicon, respectively.
The 4E-BP1 TOS Motif Mediates Raptor Binding
805
References of translation initiation by FRAP/mTOR. Genes Dev. 15,
807–826.
20. Martin, K.A., and Blenis, J. (2002). Coordinate regulation of1. Schmelzle, T., and Hall, M.N. (2000). TOR, a central controller
of cell growth. Cell 103, 253–262. translation by the PI 3-kinase and mTOR pathways. Adv. Cancer
Res. 86, 1–39.2. Fingar, D.C., Salama, S., Tsou, C., Harlow, E., and Blenis, J.
(2002). Mammalian cell size is controlled by mTOR and its down- 21. Raught, B., and Gingras, A.C. (1999). eIF4E activity is regulated
at multiple levels. Int. J. Biochem. Cell Biol. 31, 43–57.stream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16, 1472–
1487. 22. Kozak, M. (1991). Structural features in eukaryotic mRNAs that
modulate the initiation of translation. J. Biol. Chem. 266, 19867–3. Oldham, S., Montagne, J., Radimerski, T., Thomas, G., and Ha-
fen, E. (2000). Genetic and biochemical characterization of 19870.
23. Lazaris-Karatzas, A., Montine, K.S., and Sonenberg, N. (1990).dTOR, the Drosophila homolog of the target of rapamycin.
Genes Dev. 14, 2689–2694. Malignant transformation by a eukaryotic initiation factor sub-
unit that binds to mRNA 5 cap. Nature 345, 544–547.4. Zhang, H., Stallock, J.P., Ng, J.C., Reinhard, C., and Neufeld,
T.P. (2000). Regulation of cellular growth by the Drosophila tar- 24. Rousseau, D., Gingras, A.C., Pause, A., and Sonenberg, N.
(1996). The eIF4E-binding proteins 1 and 2 are negative regula-get of rapamycin dTOR. Genes Dev. 14, 2712–2724.
tors of cell growth. Oncogene 13, 2415–2420.5. Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T.,
25. Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R.,Lane, W.S., and Schreiber, S.L. (1994). A mammalian protein
Erdjument-Bromage, H., Tempst, P., and Sabatini, D.M. (2002).targeted by G1-arresting rapamycin-receptor complex. Nature
mTOR interacts with raptor to form a nutrient-sensitive complex369, 756–758.
that signals to the cell growth machinery. Cell 110, 163–175.6. Chiu, M.I., Katz, H., and Berlin, V. (1994). RAPT1, a mammalian
26. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat,homolog of yeast Tor, interacts with the FKBP12/rapamycin
S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002). Raptor,complex. Proc. Natl. Acad. Sci. USA 91, 12574–12578.
a binding partner of target of rapamycin (TOR), mediates TOR7. Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P., and
action. Cell 110, 177–189.Snyder, S.H. (1994). RAFT1: a mammalian protein that binds to
27. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo,FKBP12 in a rapamycin-dependent fashion and is homologous
J.L., Bonenfant, D., Oppliger, W., Jenoe, P., and Hall, M.N.to yeast TORs. Cell 78, 35–43.
(2002). Two TOR complexes, only one of which is rapamycin8. Sabers, C.J., Martin, M.M., Brunn, G.J., Williams, J.M., Dumont,
sensitive, have distinct roles in cell growth control. Mol. CellF.J., Wiederrecht, G., and Abraham, R.T. (1995). Isolation of a
10, 457–468.protein target of the FKBP12-rapamycin complex in mammalian
28. Schalm, S.S., and Blenis, J. (2002). Identification of a conservedcells. J. Biol. Chem. 270, 815–822.
motif required for mTOR signaling. Curr. Biol. 12, 632–639.9. Brown, E.J., Beal, P.A., Keith, C.T., Chen, J., Shin, T.B., and
29. Peterson, R.T., Desai, B.N., Hardwick, J.S., and Schreiber, S.L.Schreiber, S.L. (1995). Control of p70 s6 kinase by kinase activity
(1999). Protein phosphatase 2A interacts with the 70-kDa S6of FRAP in vivo. Nature 377, 441–446.
kinase and is activated by inhibition of FKBP12-rapamycin-10. Brunn, G.J., Hudson, C.C., Sekulic, A., Williams, J.M., Hosoi, H.,
associated protein. Proc. Natl. Acad. Sci. USA 96, 4438–4442.Houghton, P.J., Lawrence, J.C., Jr., and Abraham, R.T. (1997).
30. Lin, T.A., and Lawrence, J.C., Jr. (1997). Control of PHAS-I phos-Phosphorylation of the translational repressor PHAS-I by the
phorylation in 3T3–L1 adipocytes: effects of inhibiting proteinmammalian target of rapamycin. Science 277, 99–101.
phosphatases and the p70S6K signalling pathway. Diabetologia11. Jefferies, H.B., Fumagalli, S., Dennis, P.B., Reinhard, C., Pear-
40 (Suppl 2), S18–S24.son, R.B., and Thomas, G. (1997). Rapamycin suppresses 5TOP
31. Mader, S., Lee, H., Pause, A., and Sonenberg, N. (1995). ThemRNA translation through inhibition of p70s6k. EMBO J. 16,
translation initiation factor eIF-4E binds to a common motif3693–3704.
shared by the translation factor eIF-4 gamma and the transla-12. Tang, H., Hornstein, E., Stolovich, M., Levy, G., Livingstone,
tional repressors 4E-binding proteins. Mol. Cell. Biol. 15, 4990–M., Templeton, D., Avruch, J., and Meyuhas, O. (2001). Amino
4997.acid-induced translation of TOP mRNAs is fully dependent on
32. Hara, K., Yonezawa, K., Sakaue, H., Kotani, K., Kojima, A., Wa-phosphatidylinositol 3-kinase-mediated signaling, is partially
terfield, M.D., and Kasuga, M. (1995). Normal activation of p70inhibited by rapamycin, and is independent of S6K1 and rpS6
S6 kinase by insulin in cells overexpressing dominant negativephosphorylation. Mol. Cell. Biol. 21, 8671–8683.
85kD subunit of phosphoinositide 3-kinase. Biochem. Biophys.13. Pause, A., Belsham, G.J., Gingras, A.C., Donze, O., Lin, T.A.,
Res. Commun. 208, 735–741.Lawrence, J.C., Jr., and Sonenberg, N. (1994). Insulin-depen-
33. Kim, S., Jee, K., Kim, D., Koh, H., and Chung, J. (2001). Cyclic
dent stimulation of protein synthesis by phosphorylation of a
AMP inhibits Akt activity by blocking the membrane localization
regulator of 5-cap function. Nature 371, 762–767.
of PDK1. J. Biol. Chem. 276, 12864–12870.
14. Lin, T.A., Kong, X., Haystead, T.A., Pause, A., Belsham, G.,
34. Burnett, P.E., Barrow, R.K., Cohen, N.A., Snyder, S.H., and Sa-
Sonenberg, N., and Lawrence, J.C., Jr. (1994). PHAS-I as a batini, D.M. (1998). RAFT1 phosphorylation of the translational
link between mitogen-activated protein kinase and translation regulators p70 S6 kinase and 4E–BP1. Proc. Natl. Acad. Sci.
initiation. Science 266, 653–656. USA 95, 1432–1437.
15. Gingras, A.C., Gygi, S.P., Raught, B., Polakiewicz, R.D., Abra- 35. Heesom, K.J., and Denton, R.M. (1999). Dissociation of the
ham, R.T., Hoekstra, M.F., Aebersold, R., and Sonenberg, N. eukaryotic initiation factor-4E/4E–BP1 complex involves phos-
(1999). Regulation of 4E–BP1 phosphorylation: a novel two-step phorylation of 4E–BP1 by an mTOR-associated kinase. FEBS
mechanism. Genes Dev. 13, 1422–1437. Lett. 457, 489–493.
16. Mothe-Satney, I., Brunn, G.J., McMahon, L.P., Capaldo, C.T., 36. Gingras, A.C., Kennedy, S.G., O’Leary, M.A., Sonenberg, N., and
Abraham, R.T., and Lawrence, J.C., Jr. (2000). Mammalian target Hay, N. (1998). 4E–BP1, a repressor of mRNA translation, is
of rapamycin-dependent phosphorylation of PHAS-I in four phosphorylated and inactivated by the Akt(PKB) signaling path-
(S/T)P sites detected by phospho-specific antibodies. J. Biol. way. Genes Dev. 12, 502–513.
Chem. 275, 33836–33843. 37. Tee, A.R., and Proud, C.G. (2002). Caspase cleavage of initiation
17. Fadden, P., Haystead, T.A., and Lawrence, J.C., Jr. (1997). Iden- factor 4E-binding protein 1 yields a dominant inhibitor of cap-
tification of phosphorylation sites in the translational regulator, dependent translation and reveals a novel regulatory motif. Mol.
PHAS-I, that are controlled by insulin and rapamycin in rat adi- Cell. Biol. 22, 1674–1683.
pocytes. J. Biol. Chem. 272, 10240–10247. 38. Miron, M., Verdu, J., Lachance, P.E., Birnbaum, M.J., Lasko,
18. Heesom, K.J., Avison, M.B., Diggle, T.A., and Denton, R.M. P.F., and Sonenberg, N. (2001). The translational inhibitor 4E-
(1998). Insulin-stimulated kinase from rat fat cells that phos- BP is an effector of PI(3)K/Akt signalling and cell growth in
phorylates initiation factor 4E-binding protein 1 on the rapa- Drosophila. Nat. Cell Biol. 3, 596–601.
mycin-insensitive site (serine-111). Biochem. J. 336, 39–48. 39. Gingras, A.C., Raught, B., Gygi, S.P., Niedzwiecka, A., Miron,
M., Burley, S.K., Polakiewicz, R.D., Wyslouch-Cieszynska, A.,19. Gingras, A.C., Raught, B., and Sonenberg, N. (2001). Regulation
Current Biology
806
Aebersold, R., and Sonenberg, N. (2001). Hierarchical phosphor-
ylation of the translation inhibitor 4E–BP1. Genes Dev. 15, 2852–
2864.
40. Khokhlatchev, A., Xu, S., English, J., Wu, P., Schaefer, E., and
Cobb, M.H. (1997). Reconstitution of mitogen-activated protein
kinase phosphorylation cascades in bacteria. Efficient synthesis
of active protein kinases. J. Biol. Chem. 272, 11057–11062.
41. Murphy, L.O., Smith, S., Chen, R.H., Fingar, D.C., and Blenis,
J. (2002). Molecular interpretation of ERK signal duration by
immediate early gene products. Nat. Cell Biol. 4, 556–564.
42. Chen, R.H., Sarnecki, C., and Blenis, J. (1992). Nuclear localiza-
tion and regulation of erk- and rsk-encoded protein kinases.
Mol. Cell. Biol. 12, 915–927.
43. Martin, K.A., Schalm, S.S., Romanelli, A., Keon, K.L., and Blenis,
J. (2001). Ribosomal S6 kinase 2 inhibition by a potent C-ter-
minal repressor domain is relieved by mitogen-activated pro-
tein-extracellular signal- regulated kinase kinase-regulated
phosphorylation. J. Biol. Chem. 276, 7892–7898.
